ArticleUrology2017
Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease.
Article in Urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Inflammatory bowel disease and prostate cancer: from epidemiological controversy to mechanistic hypotheses.Frontiers in immunology · 2026Review
- Quality of life and supportive care needs in prostate cancer: the impact of treatment received and care service utilization among Māori and non-Māori patients in New Zealand.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Inflammatory Bowel Disease and Colorectal Cancer.Cancers · 2024Review
- Rectal Cancer and Radiation in Colitis.Clinics in colon and rectal surgery · 2024Review
- Review
- Inflammatory bowel disease-associated malignancies and considerations for radiation impacting bowel: a scoping review.Journal of gastrointestinal oncology · 2022Article
- Impact of inflammatory bowel disease on radical prostatectomy outcomes and costs of care.Prostate international · 2021Article
- Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients?Clinical and translational radiation oncology · 2021Article
- Ulcerative colitis that developed during radiotherapy for prostate cancer, deteriorated rapidly and required emergency surgery.Surgical case reports · 2020Article
- Inflammatory bowel disease and prostate cancer risk: A systematic review.Arab journal of urology · 2020Review
- Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Article
- Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer.Digestive diseases and sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo investigate the influences of inflammatory bowel disease (IBD), a rare but morbid disease with increasing incidence, on prostate cancer management decisions. We examined whether prostate cancer treatment differed for men with IBD, and whether treatment choice was associated with risk of IBD flare. MATERIALS AND
methodsUsing Veterans Health Administration cancer registry and administrative data, we identified 52,311 men diagnosed with prostate cancer from 2005 to 2008. We used International Classification of Diseases-9 codes and pharmacy and utilization data to identify IBD diagnoses, IBD-directed therapy, and flares (glucocorticoid escalation, hospitalization, and surgical intervention). We compared characteristics across men with and without IBD, and used multivariable regression to examine IBD flares after treatment according to treatment type.
resultsTwo hundred and forty men (0.5%) had IBD prior to prostate cancer diagnosis. Compared to non-IBD patients, IBD patients were more likely Caucasian (P < .001) with lower-risk cancer (P = .02). Surgery was more common in IBD patients (41% vs 28%, P < .001). In the year following prostate cancer treatment, 18% of IBD patients experienced flares. After adjustment, the only predictor of flare in the year after treatment was flare in the year prior to treatment (adjusted odds ratio, 12.5; 95% confidence interval, 5.4-29.2).
conclusionIBD patients were more likely to have lower-risk disease and be treated with surgery. Choice of prostate cancer treatment did not predict flares in the subsequent year. Better understanding of the intersection of IBD and prostate cancer can help inform treatment decisions for the increasing number of men managing both diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.